Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis

Summary: Background: Heart failure is associated with high morbidity, mortality, and substantial resource use. Dapagliflozin improves outcomes in heart failure, but local economic evidence for Argentina is limited. We conducted a cost-utility analysis of dapagliflozin added to standard therapy for chronic heart failure in Argentina.

Methods